Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.44 |
| ▸ | ATR | Q13535 | 3/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3903409 | 0.95 | F10 (0.48) | F10ATRIRAK4IRAK1 | |
| Trifluoroacetic Acid SCHEMBL3905869 | 0.92 | IRAK4 (0.47) | F10IRAK4IRAK1 | |
| Trifluoroacetic Acid SCHEMBL3902362 | 0.90 | F10 (0.44) | F10IRAK4IRAK1 | |
| Trifluoroacetic Acid SCHEMBL3903460 | 0.88 | F10 (0.43) | F10IRAK4IRAK1 | |
| Trifluoroacetic Acid SCHEMBL3906006 | 0.87 | ATR (0.42) | F10ATRIRAK4IRAK1PIM1 | |
| SCHEMBL5785047 | 0.87 | IRAK4 (0.51) | F10IRAK4IRAK1 | |
| SCHEMBL3910283 | 0.87 | MEN1 (0.48) | ATRIRAK4IRAK1PIM1PIM3 | |
| SCHEMBL3157157 | 0.86 | F10 (0.58) | F10 | |
| SCHEMBL3151362 | 0.86 | F10 (0.53) | F10IRAK4 | |
| Trifluoroacetic Acid SCHEMBL3916000 | 0.85 | F10 (0.46) | F10IRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1670783-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | F10 14/4885ATR 1613/4885IRAK4 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.